Acumen Pharmaceuticals, Inc. (ABOS) 2021年年度报告「NASDAQ」.pdf

1、Table of ContentsTable of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE FISCAL YEAR ENDED DECEMBER 31,2021OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

2、OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE TRANSITION PERIOD FROM TO Commission file number:001-40551 Acumen Pharmaceuticals,Inc.(Exact name of registrant as specified in its charter)Delaware 36-4108129State or other jurisdiction of(I.R.S.Employerincorporation or organization Identification No.)4

3、27 Park St.Charlottesville,VA 22902(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code(434)297-1000Securities registered pursuant to Section 12(b)of the Act:Title of each class TradingSymbol(s)Name of each exchangeon which registeredCommon stock,par val

4、ue$0.0001 per share ABOS The Nasdaq Global Select MarketSecurities registered pursuant to section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes NoIndicate by check mark if the registrant is not required t

5、o file reports pursuant to Section 13 or Section 15(d)of the Act.Yes NoIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12 months(or for such shorter period that the registrant

6、was required to file such reports),and(2)has been subject to such filing requirements for the past 90days.Yes NoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T(232.405 of this chapte